Clinical trials: Dementia Disorders
Alzheimer's Disease
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
This is a Phase I, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7105705 in two participant populations: healthy participants and…
- Trial name
- NCT02820896
- Testing
- RO7105705
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Alzheimer's Disease
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
- Trial name
- NCT05804383
- Testing
- BMS-984923
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Allyx Therapeutics
Alzheimer's Disease
Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease
The primary objective of this trial is to assess the ability of Transcranial Magnetic Stimulation with H coil to prefrontal cortex , with an addition of cognitive brain training, to improve cognitive performance in patients with…
- Trial name
- NCT01179373
- Testing
- TMS, H coil
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Brainsway
Alzheimer's Disease
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD.
- Trial name
- NCT03828747
- Testing
- Semorinemab, [18F]GTP1
- Where
- 49 sites in United States, France and 2 more
- Volunteers
- 272 people
- Sponsor
- Genentech, Inc.
Alzheimer Disease
The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
This is a 15-month study with two phases. During the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active…
- Trial name
- NCT00006187
- Testing
- Investigational drug
- Where
- 34 sites in United States
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers
This study investigates the initial safety profile of [18F]P16-129 in healthy volunteers including dosimetry determination, and compares the uptake and kinetics of [18F]P16-129 with the FDA approved drug [18F]florbetapir in the…
- Trial name
- NCT03902548
- Testing
- [18F]P16-129
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Five Eleven Pharma, Inc.
Dementia, Alzheimer Type
TRx0014 in Patients With Mild or Moderate Alzheimer's Disease
The primary objective of the study is to investigate the effects of oral TRx0014 at three doses (30, 60 and 100 mg tid) compared with placebo on cognitive ability in patients with mild or moderate dementia of the Alzheimer type.
- Trial name
- NCT00515333
- Testing
- TRx0014
- Volunteers
- 323 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer's Disease
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.
- Trial name
- NCT02585934
- Testing
- RVT-101
- Where
- 197 sites in United States, Argentina and 17 more
- Volunteers
- 1,315 people
- Sponsor
- Axovant Sciences Ltd.
HIV Infections
Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia
The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia. Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle…
- Trial name
- NCT00002414
- Testing
- CPI-1189
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Centaur Pharmaceuticals
Alzheimer Disease
Efficacy and Safety of MMFS in Early AD
This study is designed to evaluate the safety and efficacy of MMFS for improving cognition and global function in patients with probable Early Alzheimer's disease.
- Trial name
- NCT03531684
- Testing
- MMFS-205-SR
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Neurocentria, Inc.
Dementia of the Alzheimer's Type
The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease
The primary purpose of this study is to evaluate the safety and the tolerability of NEUROSTEM®-AD (Human Umbilical Cord Blood Derived Mesenchymal Stem Cells) and to assess the maximum tolerated dose (MTD).
- Trial name
- NCT01297218
- Testing
- Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Medipost Co Ltd.
Alzheimer Disease
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when…
- Trial name
- INTERCEPT-AD (NCT04931459)
- Testing
- ACU193
- Where
- 17 sites in United States
- Volunteers
- 65 people
- Sponsor
- Acumen Pharmaceuticals
Alzheimer's Disease
A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease
The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's disease.
- Trial name
- NCT00224497
- Testing
- SB-742457
- Where
- 48 sites in Austria, Bulgaria and 11 more
- Volunteers
- 380 people
- Sponsor
- GlaxoSmithKline
Dementia With Lewy Bodies (DLB)
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB.
- Trial name
- AscenD-LB (NCT04001517)
- Testing
- Neflamapimod
- Where
- 24 sites in United States, Netherlands
- Volunteers
- 91 people
- Sponsor
- EIP Pharma Inc
Huntington's Disease
A Study of the Novel Drug Dimebon in Patients With Huntington's Disease
This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive, motor, and overall function in subjects with Huntington's Disease.
- Trial name
- DIMOND (NCT00497159)
- Testing
- Dimebon
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Medivation, Inc.
Alzheimer Disease, Dementia
Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
The purpose of the study is to evaluate the change in cognitive ability and activities of daily living in patients with Alzheimer's disease (AD) as measured by specific evaluations during 18 months of dosing.
- Trial name
- NCT00105547
- Testing
- MPC-7869
- Where
- 132 sites in United States
- Volunteers
- 1,600 people
- Sponsor
- Myrexis Inc.
Vascular Dementia
Rivastigmine Capsules in Patients With Probable Vascular Dementia
The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable…
- Trial name
- NCT00130338
- Testing
- Rivastigmine
- Volunteers
- 521 people
- Sponsor
- Novartis
Alzheimer's Disease
Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers
Phase 1A SAD: Five or more cohorts of 8 healthy volunteers (HVs) will receive a single IV bolus injection of study drug or placebo. The first 4 cohorts will be male only.
- Trial name
- NCT05965414
- Testing
- CS6253 Solution for Injection
- Where
- Spain
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Artery Therapeutics, Inc.
Alzheimer's Disease
A Study of Semagacestat for Alzheimer's Patients
The primary objective of the original study was to assess the safety of semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment.
- Trial name
- Identity XT (NCT01035138)
- Testing
- semagacestat
- Where
- 71 sites in United States, Australia and 12 more
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and potential benefit of Dimebon as compared to placebo in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00377715
- Testing
- Dimebon
- Where
- Russia
- Volunteers
- 183 people
- Sponsor
- Medivation, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.